the American Association for the Advancement of Science, and the American Academy of Arts and Sciences, and a Master of the American College of Physicians. Dr. Coller served as President of the American Society of Hematology in 1997-1998 and as the founding President of the Society for Clinical and Translational Science from 2008 to 2010. He is a member of the Advisory Council of the National Heart, Lung, and Blood Institute and the national Principal Investigators’ CTSA Consortium Steering Committee. Dr. Coller’s research interests have focused on hemostasis and thrombosis, in particular platelet physiology. He developed a monoclonal antibody that inhibits platelet function and a derivative of that antibody (abciximab; ReoPro; Centocor/Eli Lilly) was approved for human use by FDA in 1994. It is now in clinical use throughout the United States, Europe, Scandinavia, Australia, and portions of Asia to prevent ischemic complications of percutaneous coronary interventions such as angioplasty and stent insertion. More than 4 million patients have been treated with abciximab. He also developed an assay to assess platelet function, and automated derivatives of that assay to monitor therapy with abciximab, aspirin, and clopidogrel (Plavix™ have been approved for human use by FDA (VerifyNow; Accumetrics). Dr. Coller is the recipient or a co-recipient of 14 U.S. patents.
Elaine K. Gallin, Ph.D. (Workshop Co-Chair), is currently a partner at QE Philanthropic Advisors, a consulting firm established in 2010 that serves nonprofits specializing in biomedical research, science and math education, and international health. From 1999 through February 2010, Dr. Gallin served as the Doris Duke Charitable Foundation’s (DDCF’s) first Program Director for Medical Research. In that capacity, she led the creation and management of a portfolio of grant programs that committed more than $185 million to supporting clinical research. Dr. Gallin also designed and led DDCF’s $65 million African Health Initiative. Launched in September 2007, this initiative supports large-scale health services delivery projects designed to provide integrated primary health care linked to rigorous operations and implementation research in several sub-Saharan African communities. Before joining DDCF, Dr. Gallin spent two decades working for the U.S. government, first as a research physiologist and then as research administrator where she last served as the Deputy Director of the Office of International Health Programs in the U.S. Department of Energy overseeing health research programs in countries of the former Soviet Union. During this period, she also spent a sabbatical year working in the Science Committee of the U.S. House of Representatives as a Congressional Science Fellow. Dr. Gallin has participated in numerous professional committees and review panels including several for the IOM and NIH. She was a founding member and the first Vice Chair of HRA (an